Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Introduction
Diagnosis of Alzheimer's disease (AD) based on amyloid beta (A), pathologic tau (T), and neurodegeneration (N) biomarkers in peripheral fluids promises to accelerate clinical trials and intercept disease earlier.
Methods
Qualification of a Simoa plasma p217+tau assay was performed, followed by clinical utility evaluation in a...
Alternative Titles
Full title
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_af870e1028d04c88b91f60d009e68c2c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_af870e1028d04c88b91f60d009e68c2c
Other Identifiers
ISSN
2352-8729
E-ISSN
2352-8729
DOI
10.1002/dad2.12204
